Antihypertensive therapy

References

• Millar-Craig MW, Bishop CN, Raftery EB. Circadian variation of blood-pressure. Lancet 1978: 1(8068): 795–7
   PubMed Web of Science ®Google Scholar
• Linsell CR Lightman SL, Mullen PE, et al. Circadian rhythms of epinephrine and norepinephrine in man. J Clin Endocrinol Metab 1985: 60(6): 1210–5
   PubMed Web of Science ®Google Scholar
• Myers A, Dewar HA. Circumstances attending 100 sudden deaths from coronary artery disease with coroner's necropsies. Br Heart J 1975: 37(11): 1133–43
   PubMedGoogle Scholar
• Craig MW, Kenny D, Mann S, et al. Effect of once-daily atenolol on ambulatory blood pressure. BMJ 1979: 1 (6158): 237–8
   PubMed Web of Science ®Google Scholar
• Raftery EB, Carrageta MO. Hypertension and beta-blockers; are they all the same? Int J Cardiol 1985: 7(4): 337–46
   PubMed Web of Science ®Google Scholar
• Zachariah PK, Schwaitz GL, Sheps SG, et al. Antihypertensive effects of a new sustained-release formulation of nifedipine. J Clin Pharmacol 1990: 30(11): 1012–9
   PubMed Web of Science ®Google Scholar
• Zachariah PK, Sheps SG, Schirger A, et al. Verapamil and 24-hour ambulatory blood pressure monitoring in essential hypertension. Am J Cardiol 1986: 57(7): 74–9D
   PubMed Web of Science ®Google Scholar
• McCormack PM, Latham AN, Mee F, et al. The efficacy and duration of action of sustained-release verapamil in essential hypertension. J Cardiovasc Pharmacol 1989: 13(Suppl 4): S34–7
   PubMed Web of Science ®Google Scholar
• Spedera S, Sosna J, Schumacher A, et al. Efficacy and safety of verapamil SR 240 mg in essential hypertension: results of a multicentric phase IV study. J Cardiovasc Pharmacol 1989: 13(Suppl 4): S47–9
   Web of Science ®Google Scholar
• Elliott HL, Meredith PA, Reid JL. Pharmacokinetic overview of doxazosin. Am J Cardiol 1987: 59(14): 78–81G
   PubMed Web of Science ®Google Scholar
• Weber MA, Drayer JI, McMahon FG, et al. Transdermal administration of clonidine for treatment of high BP. Arch Intern Med 1984: 144(6): 1211–3
   PubMedGoogle Scholar
• Weber MA. Transdermal antihypertensive therapy: clinical and metabolic considerations. Am Heart J 1986: 112(4): 906–12
   PubMed Web of Science ®Google Scholar
• Lowenthal DT, Saris S, Paran E, et al. Efficacy of Clonidine as transdermal therapeutic system: the international clinical trial experience. Am Heart J 1986: 112(4): 893–900
   PubMed Web of Science ®Google Scholar
• Burris JF, Mroczek WJ. Transdermal administration of Clonidine: a new approach to antihypertensive therapy. Pharmacotherapy 1986: 6(1): 30–4
   PubMed Web of Science ®Google Scholar
• The Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. JAMA 1982: 248(12): 1465–77
   PubMed Web of Science ®Google Scholar
• MacMahon SW, Cutler JA, Furberg CD, et al. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials. Prog Cardiovasc Dis 1986: 29 (3 Suppl 1): 99–118
   PubMed Web of Science ®Google Scholar
• Smith WM. The effects of thiazides on plasma lipids: Multiple Risk Factor Intervention Trial. Presented before Meeting of the American Heart Association Council on Epidemiology. Orlando, FL: 1978 Mar 13
   Google Scholar
• The Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial: findings related to a priori hypotheses of the trial. JAMA 1990: 263(13): 1795–801
   PubMed Web of Science ®Google Scholar
• Schnaper H, Fitz A, Frohlich E, et al. Chlorthalidone and serum cholesterol. (Letter) Lancet 1977: 2(8032): 295
   PubMed Web of Science ®Google Scholar
• Goldman AI, Steele BW, Schnaper HW, et al. Serum lipoprotein levels during chlorthalidone therapy. A Veterans Administration National Heart, Lung, and Blood Institute Cooperative Study on Antihypertensive Therapy: Mild Hypertension. JAMA 1980: 244(15): 1691–5
   PubMed Web of Science ®Google Scholar
• Grimm RH Jr, Leon AS, Hunninghake DB, et al. Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients: a double-blind controlled trial. Ann Intern Med 1981: 94(1): 7–11
   PubMed Web of Science ®Google Scholar
• Ames RP. The effects of antihypertensive drugs on serum lipids and lipoproteins. I. Diuretics. Drags 1986: 32(3): 260–78
   Web of Science ®Google Scholar
• Weidmann P, Gerber A, Mordasini R. Effects of antihypertensive therapy on serum lipoproteins. Hypertension 1983: 5(5 Pt 2): III 120–31
   Web of Science ®Google Scholar
• Thomas JR. A review of 10 years of experience with indapamide as an antihypertensive agent. Hypertension 1985: 7(6 Pt 2): II 152–6
   Web of Science ®Google Scholar
• Ames RP. The effects of antihypertensive drugs on serum lipids and lipoproteins. II. Non-diuretic drugs. Drags 1986: 32(4): 335–57
   Web of Science ®Google Scholar
• Lehtonen A. Long-term effect of pindolol on plasma lipids, apoproteins A, blood glucose, and serum insulin levels. Int J Clin Pharmacol Ther Toxicol 1984: 22(5): 269–72
   PubMed Web of Science ®Google Scholar
• Pasotti C, Capra A, Fiorella G, et al. Effects of pindolol and metoprolol on plasma lipids and lipoproteins. Br J Clin Pharmacol 1982: 13(Suppl 2): 435–9S
   Web of Science ®Google Scholar
• Frishman WH, Michelson EL, Johnson BF, et al. Multiclinic comparison of labetalol to metoprolol in treatment of mild to moderate systemic hypertension. Am J Med 1983: 75(4A): 54–67
   PubMed Web of Science ®Google Scholar
• McGonigle RJ, Williams L, Murphy MJ, et al. Labetalol and lipids. (Letter) Lancet 1981: 1(8212): 163
   PubMed Web of Science ®Google Scholar
• Sommers DK, de Villiers LS, van Wyk M, et al. The effects of labetalol and Oxprenolol on blood lipids. S Afr Med J 1981: 60(10): 379–80
   PubMed Web of Science ®Google Scholar
• Roufly J, Jaillard J. Comparative effects of prazosin and atenolol on plasma lipids in hypertensive patients. Am J Med 1984: 76(2A): 105–8
   PubMed Web of Science ®Google Scholar
• Takabatake T, Ohta H, Maekawa M, et al. Effects of long-term prazosin therapy on lipoprotein metabolism in hypertensive patients. Am J Med 1984: 76(2A): 113–6
   PubMed Web of Science ®Google Scholar
• Taylor CR, Leader JP, Singleton W, et al. Profile of trimazosin: an effective and safe antihypertensive agent. Am Heart J 1983: 106 (5 Pt 2): 1269–81
   PubMed Web of Science ®Google Scholar
• Torvik D, Madsbu HP. Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension. Br J Clin Pharmacol 1986: 21 (Suppl 1): 69–75S
   PubMed Web of Science ®Google Scholar
• Kochar MS, Kaur M, Zeller JR, et al. Treatment of essential hypertension with a twice-daily dose of Captopril. Curr Ther Res 1984: 35(5): 905–12
   Web of Science ®Google Scholar
• Ohman P, Aurell M, Asplund J, et al. A long-term follow-up of patients with essential hypertension treated with captopril. Acta Med Scand 1984: 216(1): 53–6
   PubMedGoogle Scholar
• Vessby B, Abelin J, Finnson M, et al. Effects of nifedipine treatment on carbohydrate and lipoprotein metabolism. Curr Ther Res 1983: 33(6): 1075–81
   Web of Science ®Google Scholar
• Ohman KP, Werner L, von Schenck H, et al. Antihypertensive and metabolic effects of nifedipine and labetalol alone and in combination in primary hypertension. Eur J Clin Pharmacol 1985: 29(2): 149–54
   PubMed Web of Science ®Google Scholar
• Pool PE, Seagren SC, Salel AF. Effects of diltiazem on serum lipids, exercise performance and blood pressure: randomized, double-blind, placebo-controlled evaluation for systemic hypertension. Am J Cardiol 1985: 56(16): 86–91H
   PubMed Web of Science ®Google Scholar
• Costa FV, Borghi C, Mussi A, et al. Hypolipidemic effects of long-term antihypertensive treatment with captopril: a prospective study. Am J Med 1988: 84(Suppl 3A): 159–61
   PubMedGoogle Scholar
• Lichtlen PR, Hugenholtz PG, Rafflenbeul W, et al. Retardation of angiographic progression of coronary artery disease by nifedipine: results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Lancet 1990: 335(8698): 1109–13
   PubMed Web of Science ®Google Scholar
• Castelli WP, Anderson K. A population at risk: prevalence of high cholesterol in hypertensive patients in the Framingham Study. Am J Med 1986: 80(Suppl 2A): 23–32
   PubMed Web of Science ®Google Scholar
• Ames RP. Metabolic disturbances increasing the risk of coronary heart disease during diuretic-based antihypertensive therapy: lipid alterations and glucose intolerance. Am Heart J 1983: 106(5 Pt2): 1207–14
   PubMed Web of Science ®Google Scholar
• Weinberger MH. Antihypertensive therapy and lipids: evidence, mechanisms, and implications. Arch Intern Med 1985: 145(6): 1102–5
   PubMedGoogle Scholar
• Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985: 27(5): 335–71
   PubMed Web of Science ®Google Scholar
• Stamler J, Prineas RJ, Neaton JD, et al. Background and design of the new U.S. trial on diet and drug treatment of “mild” hypertension (TOMHS). Am J Cardiol 1987: 59(14): 51–60G
   Web of Science ®Google Scholar
• Pollare T, Lithell H, Beme C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989: 321(13): 868–73
   PubMed Web of Science ®Google Scholar
• Pollare T, Lithell H, Selinus I, et al. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 1989: 298(6681): 1152–7
   PubMed Web of Science ®Google Scholar
• Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991: 14(3): 203–9
   PubMed Web of Science ®Google Scholar
• Lithell HO, Pollare T, Berne C. Insulin sensitivity in newly detected hypertensive patients: influence of captopril and other antihypertensive agents on insulin sensitivity and related biological parameters. J Cardiovasc Pharmacol 1990: 15(Suppl 5): S46–52
   PubMed Web of Science ®Google Scholar
• Pollare T, Lithell H, Selinus I, et al. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988: 31(7): 415–20
   PubMed Web of Science ®Google Scholar
• Pollare T, Lithell H, Mörlin C, et al. Metabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groups. J Hypertens 1989: 7(7): 551–9
   PubMed Web of Science ®Google Scholar
• Savage DD, Drayer JI, Henry WL, et al. Echocardiographic assessment of cardiac anatomy and function in hypertensive subjects. Circulation 1979: 59(4): 623–32
   PubMed Web of Science ®Google Scholar
• Drayer JI, Weber MA, Laragh JH. Echocardiography in the evaluation of patients with mild or borderline hypertension. In: Weber MA, ed. Treatment strategies in hypertension. Miami: Symposia Specialists Medical Books, 1981: 21–32
   Google Scholar
• Casale PN, Milner A, Devereux RB. Value of echocardiographic left ventricular mass in predicting cardiovascular morbid events in hypertensive men. (Abstr) Circulation 1985: 72(Suppl III): III 130
   Google Scholar
• Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990: 322(22): 1561–6
   PubMed Web of Science ®Google Scholar
• Messerli FH, Nunez BD, Nunez MM, et al. Hypertension and sudden death: disparate effects of calcium entry blocker and diuretic therapy on cardiac dysrhythmias. Arch Intern Med 1989: 149(Jun): 1263–7
   PubMedGoogle Scholar
• Weber MA, Drayer JI, Baird WM. Echocardiographic evaluation of left ventricular hypertrophy. J Cardiovasc Pharmacol 1986: 8 (Suppl 3): S61–8
   PubMed Web of Science ®Google Scholar
• Ventura HO, Frohlich ED, Messerli FH, et al. Cardiovascular effects and regional blood flow distribution associated with angiotensin convening enzyme inhibition (captopril) in essential hypertension. Am J Cardiol 1985: 55: 1023–6
   PubMed Web of Science ®Google Scholar
• McKenna WJ, Borggrefe M, England D, et al. The natural history of left ventricular hypertrophy in hypertrophic cardiomyopathy: an electrocardiographic study. Circulation 1982: 66(6): 1233–40
   PubMed Web of Science ®Google Scholar
• Arevalo JV. Clonidine and left ventricular function in patients with arterial hypertension. Tribuna Medica 1983: 68: 29–33
   Google Scholar
• Corea L, Bentiboglio M, Verdecchia P. Reversal of left ventricular hypertrophy in essential hypertension by early and long-term treatment with methyldopa. Clin Trials J 1981: 18: 380–94
   Google Scholar
• Messerli FH. Left ventricular hypertrophy: impact of calcium channel blocker therapy. Am J Med 1991: 90(5A): 27–31S
   Web of Science ®Google Scholar
• Ibrahim MM, Madkour MA, Mossallam R. Factors influencing cardiac hypertrophy in hypertensive patients. Clin Sci 1981: 61 (Suppl 7): 105–8S
   Web of Science ®Google Scholar
• Rowlands DB, Ireland MA, Glover DR, et al. The relationship between ambulatory blood pressure and echocardiographically assessed left ventricular hypertrophy. Clin Sci 1981: 61 (Suppl 7): 101–3S
   PubMed Web of Science ®Google Scholar
• Hill LS, Monaghan M, Richardson PJ. Regression of left ventricular hypertrophy during treatment with antihypertensive agents. Br J Clin Pharmacol 1979: 7(Suppl 2): 255–60S
   Web of Science ®Google Scholar
• Drayer JI, Gardin JM, Weber MA, et al. Changes in ventricular septal thickness during diuretic therapy. Clin Pharmacol Ther 1982: 32(3): 283–8
   PubMed Web of Science ®Google Scholar
• Reichek N, Franklin BB, Chandler T, et al. Reversal of left ventricular hypertrophy by antihypertensive therapy. Eur Heart J 1982: 3(Suppl A): 165–9
   PubMed Web of Science ®Google Scholar
• Drayer JI, Gardin JM, Weber MA, et al. Changes in cardiac anatomy and function during therapy with alpha-methyldopa: an echocardiographic study. Curr Ther Res 1982: 32(6): 856–65
   Web of Science ®Google Scholar
• Fouad FM, Nakashima Y, Tarazi RC, et al. Reversal of left ventricular hypertrophy in hypertensive patients treated with methyldopa: lack of association with blood pressure control. Am J Cardiol 1982: 49(4): 795–801
   PubMed Web of Science ®Google Scholar
• Drayer JI, Gardin JM, Weber MA, et al. Changes in cardiac muscle mass during vasodilation therapy of hypertension. Clin Pharmacol Ther 1983: 33(6): 727–32
   PubMed Web of Science ®Google Scholar
• Garland C, Barrett-Connor E, Suarez L, et al. Isolated systolic hypertension and mortality after age 60 years: a prospective population-based study. Am J Epidemiol 1983: 118(3): 365–76
   PubMed Web of Science ®Google Scholar
• Probstfield JL, Furberg CD. Systolic hypertension in the elderly: controlled or uncontrolled. In: Frohlich ED, ed. Preventive aspects of coronary heart disease. Philadelphia: FA Davis, 1990: 65–84
   Google Scholar
• Colandrea MA, Friedman GD, Nichaman MZ, et al. Systolic hypertension in the elderly: an epidemiologic assessment. Circulation 1970: 41 (2): 239–45
   PubMed Web of Science ®Google Scholar
• Shekelle RB, Ostfeld AM, Klawans HL Jr. Hypertension and risk of stroke in an elderly population. Stroke 1974: 5(1): 71–5
   PubMed Web of Science ®Google Scholar
• Dyer AR, Stamler J, Shekelle RB, et al. Hypertension in the elderly. Med Clin North Am 1977: 61(3): 513–29
   PubMed Web of Science ®Google Scholar
• Rutan GH, Kuller LH, Neaton JD, et al. Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial. Circulation 1988: 77(3): 504–14
   PubMed Web of Science ®Google Scholar
• Stamler J, Neaton JD, Wentworth DN. Blood pressure (systolic and diastolic) and risk of fatal coronary heart disease. Hypertension 1989: 13(5 Suppl): 12–12
   Google Scholar
• Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985: 1(8442): 1349–54
   PubMed Web of Science ®Google Scholar
• SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991: 265(24): 3255–64
   PubMed Web of Science ®Google Scholar
• Weber MA, Drayer JI, Gray DR. Combined diuretic and sympatholytic therapy in elderly patients with predominant systolic hypertension. Chest 1983: 83(2 Suppl): 416–8
   PubMed Web of Science ®Google Scholar
• Cheung DG, Hoffman CA, Ricci ST, et al. Mild hypertension in the elderly: a comparison of prazosin and enalapril. Am J Med 1989: 86(1B): 87–90
   PubMed Web of Science ®Google Scholar
• Drugs for hypertension. Med Lett Drugs Ther 1991: 33(842): 33–8
   PubMedGoogle Scholar
• McCall D, O'Rourke RA. Congestive heart failure: II. Therapeutic options, old and new. Mod Concepts Cardiovasc Dis 1983: 54: 61–5
   Google Scholar
• Levine TB. Role of vasodilators in the treatment of congestive heart failure. Am J Cardiol 1985: 55(2): 32–5A
   Web of Science ®Google Scholar
• Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986: 314(26): 1657–64
   PubMed Web of Science ®Google Scholar
• Schoenberger J A, Testa M, Ross AD, et al. Efficacy, safety, and quality-of-life assessment of captopril antihypertensive therapy in clinical practice. Arch Intern Med 1990: 150(Feb): 301–6
   PubMedGoogle Scholar